Animal vaccine for MERS might be the best approach, experts say

09/12/2013 |

It might be more advantageous for scientists to produce a Middle East respiratory syndrome coronavirus vaccine for animals suspected to be part of the human transmission chain rather than develop a human vaccine, according to some infectious disease specialists. The cost and time involved in obtaining regulatory approval are limiting factors for human vaccine development, while animal vaccine development is more time- and cost-effective. Animal vaccines are an underused way to protect people from zoonotic disease, says physician Tom Monath, a founder of the One Health Initiative.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI
Vice President of Finance
Urban Health Plan, Inc.
Bronx, NY
Director of Payor/Provider Contracting
U.S. Medical Management
Tryo, MI